Overview and Scope
Desmoid tumors refer to rare non-cancerous (benign) tumors that arise from connective tissue cells, usually in the fascia, which is the tissue that surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means they can grow and invade nearby structures but do not spread to distant parts of the body like traditional cancer.
Sizing and Forecast
The desmoid tumors market size has grown strongly in recent years. It will grow from $2.76 billion in 2023 to $2.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.
The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report
Segmentation & Regional Insights
The desmoid tumors market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users
North America was the largest region in the desmoid tumors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp
Major Driver Impacting Market Growth
The rising cases of cancer are expected to propel the growth of the desmoid tumor market going forward. Cancer refers to a collection of disorders that are defined by the body’s aberrant cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs and cause harm. The rising cancer cases worldwide have fueled the demand for effective and advanced chemotherapeutic agents, positively influencing the desmoid tumor market. For instance, in January 2023, according to reports published by the American Cancer Society Inc., a US-based voluntary health organization, 1.8 million new cancer cases were diagnosed in the US in 2020, and 606,520 cancer fatalities. By 2021, it was projected that the number of new cancer cases diagnosed would rise to 1.9 million, and the number of cancer deaths would increase to 608,570. Therefore, the rising cases of cancer are driving the growth of the desmoid tumor market.
Key Industry Players
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company , Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation , Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG
The desmoid tumors market report table of contents includes:
1. Executive Summary
2. Desmoid Tumors Market Characteristics
3. Desmoid Tumors Market Trends And Strategies
4. Desmoid Tumors Market – Macro Economic Scenario
5. Global Desmoid Tumors Market Size and Growth
…
32. Global Desmoid Tumors Market Competitive Benchmarking
33. Global Desmoid Tumors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Desmoid Tumors Market
35. Desmoid Tumors Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
